N/A N=117 Genetic Variation in Platelet Aggregation
Myocardial Infarction
Primary: LogEC50 Platelet Aggregation — 2.65; 2.62 nM
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=80 Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections
Complicated Urinary Tract Infection · Acute Pyelonephritis
Primary: Number of Participants With Overall Success — 36; 17 Participants
N/A N=170 Verbal Autopsy of Maternal Deaths, Stillbirths, and Neonatal Deaths in BetterBirth
Perinatal Death · Neonatal Death · Stillbirth
Primary: Cause of Death — 20; 35; 56; 50 Participants
Phase 2 N=87 Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery
Pancreatic Cancer
Primary: Safety as Measured by Number of Participants With Treatment-related Grade 3 or 4 Local and Systemic Toxicity as Defined by NCI CTCAE v3.0 — 3; 2; 4 Participants
Phase 2 N=25 Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)
Myeloproliferative Diseases
Primary: Objective Response Rate (ORR) — 16 Participants
Phase 4 N=281 A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients
Age-Related Macular Degeneration
Primary: Mean Change in Square-root Area of Geographic Atrophy (GA) From Baseline to Month 24 — 0.024; 0.050; 0.363; 0.285 mm — p=0.236
N/A N=19 The Effects of Noninvasive Brain Stimulation on Physical and Mental Functioning in Older Adults
Aging
Primary: Percent Change From Baseline to Post Intervention on Mobility — -3.0; 10.4; -6.1; 3.4 percent change of TUG time — p=0.24
Phase 2 N=24 Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma · Stage IVA Oropharyngeal Carcinoma AJCC v7 · Stage IVB Oropharyngeal Carcinoma AJCC v7
Primary: Dose Limiting Toxicity (Phase I) — 0; 0; 0; 0 Participants
N/A N=40 Impact of Symbiotic Administration on Intestinal Function of Head and Neck Patients Surgically Treated
Head and Neck Cancer · Synbiotics · Nutrition Therapy
Primary: Serum DAO Enzyme Concentration — 3; 2.5 ng/mL
Phase 3 N=106 A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer
Radiotherapy Induced Mucositis · Head and Neck Cancer
Primary: Severity of Mucositis According to the Radiation Therapy Oncology Group (RTOG) for Patients Who Had at Least One Mucositis Assessment — 14; 18 Participants
Phase 1 N=24 Ibuprofen 4% (w/v) Pivotal Bioequivalence Study
Bioequivalence of the Test Formulation
Primary: Maximum Plasma Concentration (Cmax) of Ibuprofen — 38.503; 25.162; 33.843; 26.432 μg/ml
Phase 3 N=227 Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
Arthralgia · Breast Cancer · Hot Flashes
Primary: Change in Item #3 (Average) of the Brief Pain Inventory (BPI) Average Pain From Baseline to Month 3 — -1.9; -2.0 score on a scale — p=0.4952
N/A N=10 Pain and Sensation After Regional Anesthesia - Pilot Study
Anesthesia, Conduction · Osteoarthritis, Hip
Primary: Patient Pain Score With Activity — 1.4 units on a scale
Phase 3 N=85 SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.
Transient Insomnia
Primary: Total Sleep Time (TST) — 401.82; 404.83; 397.28; 307.38 minutes
Phase 4 N=268 Effect of Simethicone on Screening Colonoscopy
Adenoma Colon
Primary: Adenoma Detection Rate — 43; 54 adenomas